Br J Cancer: The effect of RAS mutation on the overall survival of patients with early and late colorectal cancer liver metastasis

Colorectal cancer (CRC) is the third leading cause of cancer-related death in the United States.
recent years, the occurrence and mortality of CRC have decreased significantly as a result of improved screening methods and increased treatment options.
, although the overall incidence of CRC has decreased, the incidence of CRC among people under 55 years of age has increased by about 2% per year, the reasons for which are not yet known.
and environmental factors may be the cause of the increased incidence of early-onset colorectal cancer (EOCRC), obesity is now considered the main cause.
EOCRC has obvious molecular genetic heterogeneity.
previous studies have analyzed the genomic characteristics of EOCRC and late-oncigment CRC (LOCRC), and although there are many similarities in general, the researchers found significant differences in the occurrence of specific mutations.
Studies on prognostic comparison between
EOCRC and LOCRC patients have also shown contradictory results, so understanding the clinical relevance of common mutations based on the age of onset of CRC may help to develop unique treatment strategies and predict the potential impact of personalized therapy on EOCRC patients.
the effects of specific gene mutations on patients with ECRC and LOCRC after colorectal cancer liver metastasis (CLM) removal are not clear.
study on the total survival rate of patients with RAS mutations was designed to explore the effects of RAS mutations on the overall survival of EOCRC and LOCRC patients receiving colorectal cancer liver metastasis (CLM) anatomic excision.
researchers analyzed the effects of RAS mutations by age on patients with CLM liverectomy on patients with RAS, BRAF, and MSI status, using age as a classification variable and continuous variable.
the study included 573 patients, 192 EOCRC and 381 LOCRC cases.
study showed that the younger the age of onset of CRC, the greater the negative impact on the overall survival of RAS mutations in LOCRC, EOCRC and ≤40 years of age (risk ratio (HR) of 1.64, 2.03 and 2.97, respectively).
risk of death and linear regression analysis of specific age groups showed that RAS mutations had a greater impact on the survival of EOCRC patients than LOCRC.
Aggression risk of death by age, the results show that RAS mutations have a greater negative impact on the survival of EOCRC patients than in patients with LOCRC, especially in patients under 40 years of age, and should therefore be considered an important prognostic factor in the treatment strategy for the disease.
。